ArticleCellular and molecular life sciences : CMLS2026
Mediator complex subunit 8 promotes bladder cancer progression via Stearoyl-CoA desaturase.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Mediator complex subunits have recently been reported to be associated with tumor progression, the tumor immune microenvironment, and therapeutic responses. However, limited research about oncology has been conducted on Mediator complex subunit 8 (MED8). The functional role and molecular mechanism of MED8 in bladder cancer (BLCA) require further systematic bioinformatic analysis and experimental validation. Analysis of The Cancer Genome Atlas pan-cancer cohort and multiple bladder cancer datasets revealed MED8 upregulation in various tumors. More importantly, MED8 expression was correlated with poor prognosis in bladder cancer patients. In vitro proliferation and migration assays demonstrated that MED8 knockdown suppressed bladder cancer cell proliferation and motility. Conversely, MED8 overexpression promoted cellular proliferation and migration. Meanwhile, the influence of MED8 on the growth of BLCA was validated in vivo. Integrated multi-omics sequencing (RNA-seq combined with Astral-DIA proteomics) identified Stearoyl-CoA desaturase (SCD) as a potential downstream effector of MED8. Finally, rescue experiments confirmed that MED8 regulates bladder cancer cell proliferation and migration through SCD. In conclusion, this study is the first to reveal the oncogenic function and overexpression of MED8 in bladder cancer and its tumor-promoting effects are mediated through SCD regulation. These findings provide novel insights into the molecular mechanisms of bladder cancer progression and establish a theoretical foundation for targeting MED8 as a therapeutic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.